[go: up one dir, main page]

WO2008067288A3 - Methods for inhibiting foreign body response to implanted materials - Google Patents

Methods for inhibiting foreign body response to implanted materials Download PDF

Info

Publication number
WO2008067288A3
WO2008067288A3 PCT/US2007/085598 US2007085598W WO2008067288A3 WO 2008067288 A3 WO2008067288 A3 WO 2008067288A3 US 2007085598 W US2007085598 W US 2007085598W WO 2008067288 A3 WO2008067288 A3 WO 2008067288A3
Authority
WO
WIPO (PCT)
Prior art keywords
foreign body
inhibitors
gtpase activity
methods
rho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/085598
Other languages
French (fr)
Other versions
WO2008067288A2 (en
Inventor
Themis R Kyriades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2008067288A2 publication Critical patent/WO2008067288A2/en
Publication of WO2008067288A3 publication Critical patent/WO2008067288A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432Inhibitors, antagonists
    • A61L2300/434Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for inhibiting the foreign body response to implanted materials are described herein. The methods include inhibiting the formation of foreign body giant cells by administering an effective amount of an antagonist of Rho GTPase activity. In a preferred embodiment, the methods include contacting an implanted material or the adjacent tissue or bodily fluids with an effective amount of a Rho GTPase antagonist to prevent formation of multinucleated foreign body giant cells at the implantation site. Inhibitors of Rho GTPase activity may be provided separately from the implanted material, or alternatively, may be provided as a component of the external surface of the implanted material. The methods include contacting monocytes or macrophages with inhibitors of Rho family GTPase activity in amounts effective to inhibit fusion of these cells to form multinucleated foreign body giant cells. Inhibitors of Rho GTPase activity are preferably inhibitors of Rac family GTPase activity. In a preferred embodiment, the small molecule Rac inhibitor NSC23766 is used.
PCT/US2007/085598 2006-11-27 2007-11-27 Methods for inhibiting foreign body response to implanted materials Ceased WO2008067288A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86729206P 2006-11-27 2006-11-27
US60/867,292 2006-11-27

Publications (2)

Publication Number Publication Date
WO2008067288A2 WO2008067288A2 (en) 2008-06-05
WO2008067288A3 true WO2008067288A3 (en) 2008-08-07

Family

ID=39366994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085598 Ceased WO2008067288A2 (en) 2006-11-27 2007-11-27 Methods for inhibiting foreign body response to implanted materials

Country Status (1)

Country Link
WO (1) WO2008067288A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324521A1 (en) * 2010-11-26 2013-12-05 Reza Ghotbi Implant for treating or preventing an aneurysm
WO2022076700A1 (en) * 2020-10-07 2022-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of implant associated complications
WO2024049713A1 (en) * 2022-08-30 2024-03-07 Lintec Of America, Inc. Improved nerve regeneration scaffold for accelerated regrowth
EP4630014A1 (en) 2022-12-09 2025-10-15 CeMM - Forschungszentrum für Molekulare Medizin GmbH Method for optimizing t cells for immuno-therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130722A1 (en) * 2001-12-21 2003-07-10 Marx Steven O. C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO2003105923A2 (en) * 2002-06-14 2003-12-24 The Trustees Of Columbia University In The City Ofnew York Use of y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130722A1 (en) * 2001-12-21 2003-07-10 Marx Steven O. C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO2003105923A2 (en) * 2002-06-14 2003-12-24 The Trustees Of Columbia University In The City Ofnew York Use of y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOWER T L ET AL: "RhoA is activated during respiratory syncytial virus infection", VIROLOGY, vol. 283, 2001, pages 188 - 196, XP002480818 *
GOWER T L ET AL: "RhoA signalling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology", JOURNAL OF VIROLOGY, vol. 79, no. 9, May 2005 (2005-05-01), pages 5326 - 5336, XP002480817 *
ORY S ET AL: "Rho and Rac exert antagonistic functions on spreading of macrophage-derived multinucleated cells and are not required for actin fiber formation", JOURNAL OF CELL SCIENCE, vol. 113, 2000, pages 1177 - 1188, XP002480819 *

Also Published As

Publication number Publication date
WO2008067288A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2011049332A3 (en) 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
IL200561A (en) Heterocyclic aspartyl protease inhibitors or tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same and use thereof
WO2007125310A3 (en) Pharmaceutical combinations of pk inhibitors and other active agents
MX2009012066A (en) Substituted imidazopyridazines as pi3k lipid kinase inhibitors.
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
MX2009004623A (en) Imidazopyridazines as pi3k lipid kinase inhibitors.
EP2303292A4 (en) COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICROARNS AND METHODS OF USE THEREOF IN REPAIRING LASED MYOCARDIA
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
NO20091548L (en) Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors of diabetes
WO2009129301A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
EA201100119A1 (en) CHEMICAL COMPOUNDS 251
MX2009004984A (en) Methods for preserving renal function using xanthine oxidoreductase inhibitors.
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2484679A3 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
WO2009009793A3 (en) Inhibitors of akt/pkb with anti-tumor activity
WO2008089201A3 (en) Heterocyclic-substituted piperidine as orl-1 ligands
WO2011047341A3 (en) Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
MX2010007584A (en) Protein kinase inhibitors and use thereof.
WO2006135604A3 (en) Inhibitors of checkpoint kinases
IL188438A (en) Pharmacologically active benzofused five-membered heterocycles, or pharmaceutically acceptable salts and esters thereof and pharmaceutical compositions containing them and their use as inhibitors of catechol-o-methyltransferase (comt) enzyme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871580

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871580

Country of ref document: EP

Kind code of ref document: A2